{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Clinical benefit as measured by the number of patients who did not receive a RBC transfusion post-Baseline","groups":[{"description":"Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.","id":"OG000","title":"Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Clinical Benefit as Measured by the Number of Patients Who Were Not RBC Transfusion-dependent Post-Baseline","type":"SECONDARY","unitOfMeasure":"Participants"}